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Objective The mechanisms underlying the increased
cardiovascular risk (CVR) of rheumatoid arthritis (RA)
patients remain unclear. Since the recently discovered
angiogenic T cells (Tang) could have a role in endothelial
repair through cooperating with endothelial progenitor
cells (EPC), the main aim of this study was to analyse
the Tang and EPC populations in relation to disease-
speciﬁc features and traditional CVR factors.
Methods Tang (CD3+CD31+CXCR4+) and EPC
(CD34+VEGFR2+CD133+) populations were quantiﬁed
by ﬂow cytometry in peripheral blood samples from 103
RA patients and 18 matched healthy controls (HC).
Clinical features and traditional CVR factors were
obtained from clinical records, and 28-joint Disease
Activity Score was used for measuring disease activity.
Interferon (IFN) α serum levels were measured by
immunoassays.
Results Tang and EPC were strongly decreased in RA
patients. In HC, but not in patients, both populations
were positively correlated and inversely related to low
density lipoprotein- and total-cholesterol levels. Sex,
diabetes, dyslipidaemia, hypertension or obesity did not
signiﬁcantly inﬂuence Tang in patients, although
detected in smokers. However, Tang were closely related
to disease activity, autoantibody positivity and IFNα
levels. Multiple regression analysis adjusted for
traditional CVR factors conﬁrmed that only disease
activity, age at diagnosis, antinuclear antibody positivity
and smoking habit could predict Tang frequency. Finally,
patients who had suffered a CV event since their RA
diagnosis presented higher Tang decrease and IFNα
levels than those who were CV event-free.
Conclusions Disease-speciﬁc parameters, including
disease activity, autoantibody proﬁles and IFNα levels,
are associated with Tang decrease in RA, thus probably
accounting for CVR.
INTRODUCTION
An increased prevalence of cardiovascular (CV)
events, not fully explained by traditional risk
factors,1 has been widely reported in rheumatoid
arthritis (RA) patients.2 3 Therefore, other causes,
such as disease activity, chronic inﬂammation,
glucocorticoid treatment and genetic background,
have been proposed as disease-related independent
risk factors.3–9 Such factors could increase CV risk
by promoting the development of early atheroscler-
otic lesions and impairing the endothelial repair
mechanisms. Moreover, it has been reported that
endothelial repair mechanisms were impaired in RA
and other autoimmune diseases, partly due to the
altered number or function of endothelial progeni-
tor cells (EPC), a haematopoietic-derived popula-
tion involved in vasculogenesis and vascular
repair.10
Although EPC levels have been considered as a
surrogate marker of CV status in healthy sub-
jects,11 12 different and even contradictory data
about their role in RA patients have been reported.
Recently, a novel T cell subset, the so-called angio-
genic T cells (Tang),13 has been described that
seems to cooperate with EPCs and enhance endo-
thelial repair function, possibly through the secre-
tion of proangiogenic cytokines. In fact, in vitro
experiments showed that Tang depletion could
abrogate EPC functionality.13 Animal models of
ischaemia also highlighted the relevance of the
Tang population in capillary formation.13 Tang cells
are characterised by the coexpression of CD3,
CD31 (platelet endothelial cell adhesion molecule)
and CXCR4 (receptor for stromal-cell-derived
factor-1) and may express CD4 or CD8. This
subset is characterised by the coexpression of naive
and memory markers, thus revealing its heteroge-
neous nature. A recent study in human patients
revealed, for the ﬁrst time, that lower Tang
numbers are associated with vascular disease.14
Thus, Tang may be used as a novel putative bio-
logical marker for CV disease.
On the other hand, among other factors that
could impair endothelial repair, type I interferon
(IFN) deserve to be noted. IFNα and related cyto-
kines are a family of pleiotropic molecules with
potent antiviral effects and an established relevance
in systemic autoimmunity.15 However, increasing
evidence points out their roles in endothelial injury
and repair failure. In fact, several mechanisms by
which IFNα could damage the endothelium have
been described.16–19 In addition, this cytokine has
been associated with the occurrence of CV disease
in systemic lupus erythematosus independent of
traditional CV risk factors.20 Similar conclusions
have been reached by our group when studying RA
patients.21
Given the very recent description of the Tang
population, no such studies in RA patients have yet
been reported. Thus, we hypothesised that the
increased CV risk of RA patients could be related
to altered numbers of Tang cells. Therefore, the
main aims of the present study were: (i) to quantify
Tang population in RA patients, (ii) to evaluate clin-
ical parameters that could be associated with these
cells and (iii) whether IFNα serum levels could
inﬂuence Tang numbers in these patients.
Rodríguez-Carrio J, et al. Ann Rheum Dis 2014;0:1–7. doi:10.1136/annrheumdis-2013-204250 1



































































































































Our study involved 103 RA patients consecutively recruited
from the outpatient clinic from the Rheumatology Department
at the Hospital Universitario Central de Asturias, fulﬁlling the
1987 American College of Rheumatology criteria. Routine clin-
ical examination, including 28-joint Disease Activity Score
(DAS28) calculation, was performed during the patients’ visit.
Then, patients’ clinical records were exhaustively revised so as
to obtain previous therapies, traditional CV risk factors and his-
tories of previous CV events. Deﬁnition and classiﬁcation of CV
events and traditional risk factors (hypertension, diabetes, dysli-
pidaemia, obesity and smoking) was performed as previously
established.22 23 A CV event was considered if the patient suf-
fered from heart failure, ischaemic heart disease or cerebrovas-
cular accident since their RA diagnosis to the time of sampling.
Simultaneously, matched healthy volunteers (n=18; 15 women;
age range 23–63 years) without any pathology or treatment
were recruited from the Centro Comunitario de Sangre y
Tejidos de Asturias. Automatised blood count and serum lipids
analysis were carried out for all the participants. Approval for
the study was obtained from the Regional Ethics Committee for
Clinical Investigation, according to the Declaration of Helsinki
and all the participants gave written informed consent.
Flow cytometry analyses
EPC and Tang frequencies were measured by ﬂow cytometry.
EPCs were quantiﬁed as previously described.22 Tang were
stained with anti-CD3 PerCP-Cy5,5, anti-CD31 FITC and
CXCR4 PE-Cy7, and those CD31/CXCR4+ were considered
Tang (ﬁgure 1A) (see online supplementary text).
Cytokine serum level quantiﬁcation
Serum aliquots were stored at −80°C until cytokine measure-
ments. IFNα and tumour necrosis factor (TNF)α serum levels
were analysed by immunoassays (see online supplementary
text).
In vitro cultures
Peripheral blood mononuclear cell (PBMC) cultures were
carried out to investigate the effect of IFNα, TNFα and patients’
serum on Tang frequency in vitro (see online supplementary
text).
Statistical analysis
All data are presented as median (IQR) unless otherwise stated.
Mann–Whitney, Spearman’s ranks, ANOVA, χ2 tests and multi-
variate regression analysis were used as appropriate. A p
value<0.05 was considered statistically signiﬁcant (see online
supplementary text).
RESULTS
Angiogenic–T cells were reduced in RA patients
To evaluate Tang cells in RA patients in relation to
EPC-mediated endothelial repair ability and traditional CV risk
factors, blood samples from 103 RA patients and 18 healthy
controls (HC) were analysed by ﬂow cytometry, quantifying
Tang population by means of their CD3, CD31 and CXCR4
expression (ﬁgure 1A), whereas EPC populations were deter-
mined according to their CD34, CD133 and VEGFR2 expres-
sion, as previously described.24 Demographic and clinical
characteristics of patients were summarised in table 1. Results
showed a strong decrease of Tang population in RA patients
compared with HC, both in absolute numbers (ﬁgure 1B) and
as a percentage of T cells (2.06 (1.89)% vs 5.52 (4.77)%,
p=0.0002). Circulating EPCs, as previously reported, were also
decreased in patients (ﬁgure 1C).
On the other hand, we observed interesting associations
between Tang and CV risk factors in HC that were absent in RA
patients (table 2). First, these cells exhibited a strong positive
correlation with EPC levels. Of note, this association was found
with CD34+CD133+VEGFR2+ cells (the so-called ‘true EPC’),
but not with total CD34+ or CD34+CD133+ progenitor cells
or with the CD34+VEGFR2+ population. In addition, Tang
from HC were negatively associated with total cholesterol and
low density lipoprotein (LDL)-cholesterol, but not with high
density lipoprotein. Furthermore, EPC levels from HC showed
similar correlations (total cholesterol: r=−0.573, p=0.013;
LDL-cholesterol: r=−0.562, p=0.015), thus supporting the
association of both Tang and EPC populations with CV risk
factors. Nevertheless, these correlations were completely absent
in RA patients. Moreover, male sex and the presence of dia-
betes, hypertension, dyslipidaemia or obesity did not signiﬁ-
cantly inﬂuence Tang in RA patients, although even lower levels
were detected in smokers (p=0.037).
Finally, a stronger Tang–blood decrease was found in the sub-
group of RA patients who had suffered a CV event since their
RA diagnosis (n=19, time between RA diagnosis and CV event:
70.56±61.11 months) when compared with those without this
complication (2.61 (1.88) vs 3.56 (3.75)·103 cells/μL,
p=0.014). Thus, we analysed the inﬂuence of traditional CV
risk factors in RA patients with and without previous history of
CV events using logistic regression modelling. We found that
none of the variables included in the analysis were signiﬁcantly
associated with the occurrence of a CV event (age: p=0.704,
male sex: p=0.074, obesity: p=0.958, hypertension: p=0.079,
dyslipidaemia: p=0.569, diabetes: p=0.211 and smoking habit:
p=0.840). Therefore, traditional CV risk factors did not appear
to be the most relevant causes for Tang decrease in RA patients.
Disease activity and autoantibodies inﬂuenced Tang in RA
patients
Therefore, we aimed to look for disease-speciﬁc features which
may be involved in Tang reduction in peripheral blood. Among
the analysed clinical parameters, the strongest association was
detected with DAS28 score (ﬁgure 2A), indicating that disease
activity plays an important role in Tang decrease. Moreover,
Tang and EPC levels remained correlated, although at a lower
degree than in HC, in patients with low disease activity
(DAS28<2.6, n=27) (ﬁgure 2B). This association was com-
pletely lost in patients with active disease (DAS28≥2.6, n=76).
Other clinical parameters such as tender joint counts (r=
−0.260, p=0.009), erythrocyte sedimentation rate (r=−0.330,
p=0.001) and age at diagnosis (r=−0.352, p<0.0001), but not
disease duration (r=0.009, p=0.929), were negatively corre-
lated with Tang population. In fact, the analysis of RA patients
recruited at diagnosis and without treatment (n=7) indicated
that Tang were strongly decreased even at early stage of the
disease compared with HC (3.98 (4.13)·103 vs 8.93 (6.63)·103
cells/μL, p=0.006), showing similar levels as they established
disease counterparts (3.30 (3.28)·103 cells/μL).
Likewise, the analysis of immunological features showed that
presence of autoantibodies was also related with Tang–blood
population, since patients presenting rheumatoid factor (RF),
anticyclic citrullinated peptide antibody (anti-CCP) or antinuc-
lear antibody (ANA) exhibited lower Tang levels than their nega-
tive counterparts (ﬁgure 2C). In fact, Tang were negatively
2 Rodríguez-Carrio J, et al. Ann Rheum Dis 2014;0:1–7. doi:10.1136/annrheumdis-2013-204250

































































































































associated with RF and ANA titres (r=−0.473, p<0.0001 and
r=−0.252, p=0.011, respectively). Additionally, patients with
previous CV events presented higher frequency of anti-CCP
(88.9% vs 62.5%, p=0.031) and a trend for RF positivity
(83.3% vs 62.5%, p=0.091).
Therefore, in order to evaluate the relevance of clinical and
immunological features in determining Tang frequencies, a
multivariate linear regression analysis were performed. After
adjusting for traditional CV risk factors (age, sex, dyslipidaemia,
diabetes, hypertension, obesity and smoking), only disease activ-
ity (B (95% CI) −0.546 (−1.008 to −0.339), p=0.0001), age at
diagnosis (−0.041 (−0.088 to −0.018), p=0.003), ANA positiv-
ity (−1.046 (−1.959 to −0.184), p=0.019) and smoking
(−0.732 (−2.189 to −0.374), p=0.006) showed a signiﬁcant
effect in predicting Tang levels, thus supporting that, except for
smoking, disease-speciﬁc parameters rather than traditional CV
risk factors, are implicated in Tang numbers in RA patients.
IFNα levels were associated with Tang decrease in
peripheral blood
In addition to clinical parameters, other factors involved in RA
pathogenesis and inﬂammation burden could have a role in
Tang frequency reduction. Thus, to evaluate possible serum
markers associated with endothelial damage, we quantiﬁed cir-
culating IFNα and TNFα, two cytokines involved in the patho-
genesis of several autoimmune diseases. Results showed that
serum levels of IFNα were signiﬁcantly increased in patients
(p=0.004) (see online supplementary table S1) and correlated
inversely with Tang (ﬁgure 3A). Although IFNα was undetect-
able in the 49.3% of patients, this association remained signiﬁ-
cant in the IFNα-detectable subgroup (r=−0.233, p=0.048),
which displayed lower Tang levels (2.64 (3.03)·103 vs 4.51
(4.48)·103 cells/μL, p=0.004). This relationship was completely
absent in HC (r=−0.028, p=0.918), probably because IFNα
was undetectable in most of them (88%). No associations with
total CD3 or CD31 cells were found, suggesting that detrimen-
tal effects were speciﬁc for Tang population rather than a gener-
alised effect on T cells. Moreover, RA patients with previous CV
events exhibited higher IFNα serum levels compared with those
without them (p=0.019, 78% of IFNα positive). On the other
hand, TNFα levels, also increased in patients (p=0.014), failed
to exhibit a signiﬁcant association with Tang numbers (see
online Q6supplementary ﬁgure S2A), although patients with the
highest levels (>80th percentile, 39.49 pg/mL) showed a trend
to lower Tang counts (2.49 (1.74)·103 vs 3.92 (3.93)·103 cells/
μL, p=0.081). No signiﬁcant differences were detected in
patients with previous CV events (p=0.573).
Finally, culture assays were performed in order to evaluate the
effects of these cytokines on Tang population. Thus, PBMCs
were cultured for 4 days in medium alone or in the presence of
IFNα (1000 U/mL). Tang frequency was signiﬁcantly reduced
(up to a 26.6%) in IFNα-treated cells (ﬁgure 3B), although the
total amount of viable T lymphocytes was similar in both cul-
tures (p=0.516). Therefore, to determine the possible effect of
the IFNα present in RA serum, PBMCs were cultured in
medium supplemented with 10% of pooled sera from either
HC or RA patients and with increasing concentrations of
anti-IFNα or control rabbit IgG antibodies added to RA serum.
At day 4, RA serum-treated cells displayed a strong Tang
decrease compared with those HC-treated that was partially
restored, dose-dependently, by anti-IFNα blockade. No differ-
ences in total CD3 counts were observed after IFNα or RA
serum treatment. Moreover, the Annexin V/7-AAD Q7staining
showed that both early and late Tang apoptosis was not different
Figure 1 Tang and endothelial progenitor cell (EPC) are decreased in peripheral blood of rheumatoid arthritis (RA) patients. (A) Representative
CD31 versus CXCR4 dot-plots of a healthy controls (HC) and a RA patient. Gated CD3 lymphocytes were analysed for CD31 and CXCR4 expression
by ﬂow cytometry. Tang population was identiﬁed as the triple-positive CD3/CD31/CXCR4 cells in the lymphocyte gate. Quadrants were set
according to the ﬂuorescence signal provided by the isotype controls. Box plots represent Tang (B) and EPC (C) peripheral blood reduction in RA
patients compared with HC. Differences were evaluated by Mann–Whitney U test.
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in IFN-treated cultures than in the negative control (early: 0.53
±0.21 vs 0.82±0.28, p=0.114; late: 0.16±0.20 vs 0.08±0.07,
p=0.771). However, IFNα seemed to be able to downregulate
CXCR4 expression (MFI in Tang: 7630.50±1575.82 vs
5318.50±3253.80; in CD3 cells: 4359±799.23 vs 3606.25
±454.77), thus being one potential mechanism to explain lower
Tang numbers.
These results point out the detrimental role of IFNα on Tang
subset and the involvement of other serum factors in this effect.
In fact, TNFα was also able to slightly decrease Tang frequencies
(7.4%) in vitro (see online supplementary ﬁgure S2B), although
no associations were observed in patients.
DISCUSSION
In recent years, several studies have been performed to explore
the mechanisms underlying the increased CV risk and endothe-
lial damage observed in RA patients. The results presented
herein are the ﬁrst reporting a new factor that seems to be impli-
cated in this condition: the recently described subpopulation of
immune cells, the so-called Tang.
It has been suggested that Tang cells may be used as a bio-
marker for CV risk and endothelial function.13 Accordingly, the
evaluation of Tang cells in healthy individuals performed in this
work showed that this population was negatively correlated
with total and LDL-cholesterol levels. In addition, Tang were
positively associated with CD34+VEGFR2+CD133+ cells, the
true EPC population, but not with other phenotypes
(CD34+VEGFR2+ or CD34+CD133+). This result highlights
the special relevance of CD133 labelling for EPC measurements
by ﬂow cytometry.25 Although a positive correlation between
Tang and EPC colonies in vitro has been previously reported,13
this is the ﬁrst study showing a correlation between EPC and
Tang in human peripheral blood. These ﬁndings suggest a con-
nection between decreased Tang numbers and increased CV
risk.
The most important ﬁnding of our work, however, was the
striking circulating Tang decrease detected in RA patients,
even at diagnosis, which, additionally, was unrelated to EPC
levels and traditional CV risk factors, except for smoking.
Instead, disease activity and presence of autoantibodies
seemed to have detrimental effects on the Tang population.
These cells were decreased in a disease activity-dependent
manner in RA patients, thus suggesting that speciﬁc disease
features were implicated in Tang decrease. In fact, the associ-
ation between EPC and Tang was partially recovered in
patients with low disease activity. These ﬁndings are in line
with the idea that an accurate control of the disease will have
a positive impact on CV risk management.26 However, our
data could support an alternative role of Tang in chronic
Table 1 Demographic and clinical parameters of RA patients
RA patients (n=103)
Gender (female : male) 83:20
Age at sampling, years (mean±SD) 54.81±14.37
Disease features
Disease duration, years (mean (range)) 5.58 (0–30.00)
Age at diagnosis, years 47.83 (13.92)
Disease activity (DAS28) 3.49 (1.90)
Tender joint count 2.00 (4.00)
Swollen joint count 1.00 (3.00)
Patient global assessment (0–100) 37 (36.50)
ESR, mm/h 13.00 (22.50)
CRP, mg/L 2.00 (3.90)
HAQ (0–3) 0.87 (1.21)
RF (+), n (%) 65 (63.1)
αCCP (+), n (%) 66 (64.0)
ANA (+), n (%) 51 (49.1)
Shared epitope, n (%) 41 (39.8)
Erosive disease, n (%) 48 (46.6)




Obesity (BMI>30) 20 (19.4)
Smoking habit 34 (33.0)
CV events, n (%)
Previous CV events 18 (17.4)
Ischaemic heart disease 8 (7.7)
Heart failure 8 (7.7)
Cerebrovascular accidents 2 (1.9)
Treatments, n (%)
None or NSAIDs 7 (6.7)
Glucocorticoids 56 (54.3)
Methotrexate 77 (74.7)
TNFα blockers 44 (42.7)
Tocilizumab 12 (11.6)
Statins 20 (19.4)
Categorical variables are summarised as n (%), and continuous one as median (IQR)
unless otherwise was stated.
αCCP, cyclic citrullinated peptide antibody; ANA, antinuclear antibody; BMI, Body
Mass Index; CRP, C reactive protein; CV, cardiovascular; DAS28, 28-joing Disease
Activity Score; ESR, Erythrocyte Sedimentation Rate; HAQ, Health Assessment
Questionnaire; NSAIDs, non-steroidal anti-inflammatory drugs; RA, rheumatoid
arthritis; RF, rheumatoid factor; TNFα, tumour necrosis factor α.
Table 2 Associations of angiogenic T cells with EPC populations
and CV risk factors
HC RA
EPC populations








Traditional CV risk factors
Total cholesterol (mg/dL) r=−0.688 r=0.040
p=0.002 p=0.709
HDL-cholesterol (mg/dL) r=−0.099 r=0.112
p=0.695 p=0.300
LDL-cholesterol (mg/mL) r=−0.670 r=0.107
p=0.002 p=0.325
Male sex p=0.360 p=0.282
Diabetes p=0.712
Hypertension p=0.570
Obesity (BMI >30) p=0.119
Smoking habit p=0.037
Associations between Tang and continuous variables were assessed by Spearman
rank correlations (r coefficient and p value are shown), and Mann–Whitney U test
was used with categorical variables (p value is shown).
BMI, Body Mass Index; CV, cardiovascular; EPC, endothelial progenitor cell;
HC, healthy controls; HDL, high density lipoprotein; LDL, low density lipoprotein;
RA, rheumatoid arthritis.
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inﬂammation, since Tang behaviour under this situation is yet
unknown. In fact, it might be expected that Tang–blood cells
would migrate to the inﬂamed tissues, thus explaining the
low circulating counts and the inverse relationship with
inﬂammatory markers. Therefore, we cannot exclude that
Tang cells in patients with an active inﬂammatory disease
could be involved in the chronic inﬂammation rather than in
angiogenic repair.
On the other hand, Tang were also associated with late age at
diagnosis and the presence of ANA, RF and anti-CCP anti-
bodies, all of them previously associated with poor prognosis
and CV risk in RA.27 28 Moreover, autoantibody positivity has
been previously related to CV events in RA29 and other clinical
conditions.30 31 Therefore, our data suggest that the negative
effect of autoantibodies on Tang could be one of the underlying
mechanisms by which they inﬂuenced CV risk, at least in RA.
Figure 2 Disease activity and
autoantibody positivity were associated
with Tang decrease. (A) Tang cells
were decreased in rheumatoid arthritis
(RA) patients in a disease
activity-dependent manner and (B)
were positively correlated with
endothelial progenitor cells (EPC)
populations in inactive patients
(Disease Activity Score (DAS)<2.6,
n=27) but not in active ones
(DAS≥2.6, n=66). (C) Autoantibodies
positivity (rheumatoid factor (RF):
n=65, α cyclic citrullinated peptide
antibody (CCP): n=66 and antinuclear
antibody (ANA): n=51) was associated
with Tang reduction. Correlations were
assessed by Spearman ranks test and
differences were evaluated by Mann–
Whitney U test.
Figure 3 Interferon (IFN)α exhibited negative effects on Tang population. (A) IFNα serum levels were negatively correlated with Tang frequency in
rheumatoid arthritis (RA) patients. (B) Peripheral blood mononuclear cell (PBMC) cultured in the presence or absence (medium) of 1000 U/mL of
recombinant human IFNα prompted an in vitro Tang reduction, which was totally abrogated by IFNα blockade. A similar decrease was observed
when culturing in the presence of RA pool serum (IFNα: 159.65 pg/mL; TNFα: 88.63 pg/mL) compared with those healthy controls sera-treated
(IFNα: undetectable; TNFα: 5.09 pg/mL). Serum RA-treated reduction was partially recovered by IFNα blockade in a dose-dependent fashion:
1 μg/mL ( ) and 10 μg/mL (▪). Independent cultures were performed with freshly isolated PBMC from different blood donors (n=7). Correlations
were analysed by Spearman ranks test and differences between among treatments were evaluated by a repeated measures ANOVA and Bonferroni
post hoc test. Horizontal bars represent the mean value ***p<0.001, **p<0.01.
Rodríguez-Carrio J, et al. Ann Rheum Dis 2014;0:1–7. doi:10.1136/annrheumdis-2013-204250 5

































































































































According to our results, disease-speciﬁc features rather than
traditional CV risk factors, apart from smoking, appear to be asso-
ciated with Tang reduction in RA, thus supporting the idea that
new factors should be taken into account in CV risk assessment in
RA. In line with this, an interesting result of this work was the sug-
gested harmful role played by IFNα on Tang cells. Type I IFN sig-
nature has been widely associated with the pathogenesis of
autoimmunity, ﬁrst in SLE,32 but currently also in a subset of RA
and other disorders.15 33 34 Moreover, type I IFNs have been asso-
ciated with disease activity35 and clinical features36 37 as well as
with atherosclerosis markers19 38 39 and CV disease.20 In fact, dif-
ferent ways by which IFNα could damage the endothelium have
been described.40 Additionally, IFNα treatment has been asso-
ciated with increased CVevents in non-RA subjects.41–43 Thus, the
role of IFNα in Tang decrease reported here may suggest a new
way by which this cytokine could have a negative impact on endo-
thelial repair and CV risk, in the subgroup of RA patients with the
IFNα ‘signature’.15 34 Recently, systemic disease has been asso-
ciated with the occurrence of CV events in RA patients.44 Our
results are in line with all these ﬁndings, since patients with higher
IFNα levels are characterised by a higher rate of CV events and
lower Tang frequencies. Thus, in addition to inﬂammatory and
disease-speciﬁc markers, high IFNα levels might be helpful in the
identiﬁcation of RA patients with high CV risk.
Finally, the analysis of patients with a history of CV events
may support the use of Tang as a putative marker of endothelial
damage and CV disease in RA, as was suggested in other path-
ologies.14 These patients exhibited lower Tang counts than
those CV-free, highlighting the role of Tang cells in vascular
repair. These patients also displayed increased levels of IFNα,
previously associated with the development of premature ath-
erosclerosis20 39 and CV disease19 in lupus. Accordingly, type I
IFN signature has been found to be upregulated even several
years after CV event occurrence.17 Therefore, Tang cells could
be an interesting target in RA and CV disease.
In conclusion, our data indicate that peripheral Tang decrease,
in addition to an altered EPC function, is associated with the
increased CV risk in RA patients, probably by impairing endo-
thelial repair. These low Tang levels are closely related to
disease-speciﬁc parameters. Speciﬁcally, high disease activity and
autoantibody positivity are strong indicators of Tang reduction,
whereas presence of high IFNα levels could be considered an
additional factor in a subgroup of patients. We cannot exclude,
however, that severe disease, chronic inﬂammation and IFNα
can directly promote endothelial dysfunction, thus increasing
CV risk independently of Tang population. In any case, these
disease features could be interesting tools to account for CV risk
in RA patients. Although further studies are needed to investi-
gate the functionality of these cells in inﬂammatory conditions,
increasing Tang number and/or function might be a promising
intervention in RA patients, mainly in those with high risk or
history of CV disease. In this sense, IFNα blockade45 could be a
valuable therapy for patients with high levels of this cytokine.
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